by Yannis Natsis | Jun 30, 2020 | COVID-19, Universal Access and Affordable Medicines | Analysis & Opinion, Universal Access and Affordable Medicines | Latest Developments
In recent weeks, there have been some notable developments in relation to the procurement of potential vaccines against COVID19. On June 3, France, Germany, the Netherlands and Italy announced the formation of the Inclusive Vaccine Alliance (IVA) in order to negotiate... 
by Yannis Natsis | Apr 6, 2020 | COVID-19, Universal Access and Affordable Medicines | Analysis & Opinion
Download the article How will pharma price the products against COVID-19, be they anti-viral therapies and/or a vaccine? As the pandemic hits Europe and the U.S., pharma is firmly in the spotlight as society turns to them hoping that some therapeutics will be... 
by Yannis Natsis | Feb 6, 2020 | Universal Access and Affordable Medicines | Analysis & Opinion
2020 is a special year for the EU policy world. During the second half of last year, we heard a lot about the overarching themes of the von der Leyen Commission. For the next eleven months, there will be a lot of pushing and turning – and lobbying money spent- to zoom... 
by European Public Health Alliance | Oct 24, 2019 | Universal Access and Affordable Medicines | Analysis & Opinion
By Ellen ‘t Hoen LLM PhD, Medicines Law & Policy Patents and other forms of exclusive rights, such as data exclusivity and market exclusivity, are meant to stimulate innovation by rewarding innovators with temporary monopolies over their innovations. These... 
by European Public Health Alliance | Oct 24, 2019 | Universal Access and Affordable Medicines | Analysis & Opinion
By Charlotte Roffiaen, France Assoc Santé In France, shortages of medicines have regularly made the headlines over the past 12 months. Their numbers have indeed skyrocketed since 2008, from 44 to 868 in 2018, with a further 60% increase expected in 2019. In recent... 
by European Public Health Alliance | Oct 24, 2019 | Universal Access and Affordable Medicines | Analysis & Opinion
Denis Lacombe, Director General, European Organisation for Research and Treatment of Cancer Bringing therapeutic innovation and latest science to patients while keeping patient interests at the centre is a challenging mission. Precision medicine and new approaches to...
